Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
08/2003
08/26/2003US6610323 An enteric coated pharmaceutical dosage form comprising an H+,K+- ATPase inhibitor is disclosed. The dosage form comprises at least two portions of the H+,K+- ATPase inhibitor to be released in at least two consecutive pulses.
08/26/2003US6610322 Liposome suspension forms spontaneously upon adding a diacylglycerol-PEG lipid to an aqueous solution when the lipid has appropriate packing parameters and the adding occurs above the melting temperature of the lipid. Combinations of lipids
08/26/2003US6610272 Medicinal aerosol formulation comprising pioglitazone hydrochloride and a protective colloid amino acid stabilizer
08/26/2003US6610206 Buffered compositions for dialysis
08/26/2003US6610043 Tissue volume reduction
08/25/2003CA2405347A1 Medicament comprising nk4 gene or recombinant nk4 protein
08/22/2003CA2418930A1 Use of agents that modulate pde11a activity
08/21/2003WO2003068983A1 Use of the axl receptor for diagnosis and treatment of renal disease
08/21/2003WO2003068970A1 Sodium-independent transporter carrying acidic amino acid and its gene
08/21/2003WO2003068968A2 Mutated gene coding for a lat protein and the biological applications thereof
08/21/2003WO2003068957A1 METHOD OF SCREENING INK4 FAMILY GENE EXPRESSION CONTROLLER AND p19 GENE PROMOTER
08/21/2003WO2003068936A2 Inhibition of lung metastases by aerosol delivery of p53 gene and anti-cancer compounds
08/21/2003WO2003068929A2 Methods of inhibiting hiv-1 vpr activity and hiv-1 infectivity using atr or rad17 inhibitors
08/21/2003WO2003068803A2 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof
08/21/2003WO2003068768A1 Imidazole 4-carboxamide compounds with adenosine deaminase inhibiting activity
08/21/2003WO2003068746A1 Aryl ureas as kinase inhibitors
08/21/2003WO2003068270A1 Method of radio-labelling biomolecules
08/21/2003WO2003068265A1 Methods and compositions for treating hyperproliferative conditions
08/21/2003WO2003068264A1 New medicinal compositions on the basis of anticholinergic agents and egfr kinase inhibitors
08/21/2003WO2003068257A1 Cancer therapy
08/21/2003WO2003068253A1 Methods and compositions for the treatment of eye diseases
08/21/2003WO2003068244A1 Methods of inhibiting orthopoxvirus replication with nucleoside compounds
08/21/2003WO2003068240A1 Alpha-substituted heteroarylalkyl phosphonate derivattives
08/21/2003WO2003068235A1 Nicotinamide derivatives useful as pde4 inhibitors
08/21/2003WO2003068234A1 Nicotinamide derivatives and a tiotropium salt in combination for the treatment of e.g. inflammatory, allergic and respiratory diseases
08/21/2003WO2003068233A1 Nicotinamide derivatives and a tiotropium salt in combination for the treatment of e.g. inflammatory, allergic and respiratory diseases
08/21/2003WO2003068232A1 Nicotinamide derivatives useful as pde4 inhibitors
08/21/2003WO2003068225A1 Microglia inhibitors for interrupting immune reactions induced by interleukin 12 and ifn$g(g)
08/21/2003WO2003068224A2 Use of inhibitors of the sodium-dependent chloride-bicarbonate-exchanger for treating thrombotic and inflammatory diseases
08/21/2003WO2003068223A1 Aryl ureas with raf kinase and angiogenesis inhibiting activity
08/21/2003WO2003068217A1 Biphenil derivatives and their use as antiandrogenic agents
08/21/2003WO2003068214A1 Novel preventive for infections
08/21/2003WO2003068212A1 Use of sodium/hydrogen exchange inhibitors from the treatment of thrombotic and inflammatory diseases
08/21/2003WO2003068211A1 Methods of treating attention deficit/hyperactivity disorder (adhd)
08/21/2003WO2003068208A1 Methods of reducing angiogenesis
08/21/2003WO2003068207A2 Partial dopamine-d2 receptor agonist plus serotonin and/oder noradrenaline inhibitor activity
08/21/2003WO2003068206A1 Pharmaceutical compositions comprising terbutaline or salbutamol in combination with guaiphenesine
08/21/2003WO2003068203A1 Use of a combination of a non-steroidal anti-inflammatory agent and guaifenesin for the treatment of acute pain
08/21/2003WO2003068197A1 Method for systemic drug delivery through the nail
08/21/2003WO2003068188A1 Combination therapy for respiratory disorders
08/21/2003WO2003068171A2 Method and composition for treatment of inflammation and aids-associated neurological disorders
08/21/2003WO2003068168A2 Helical peptidomimetics and use b-amyloid-associated diseases
08/21/2003WO2003068166A2 Treatment of ophthalmic disorders using urea and urea derivatives
08/21/2003WO2003068164A2 Dosing regimen for gemcitabine hcv therapy
08/21/2003WO2003068162A2 Modified fluorinated nucleoside analogues
08/21/2003WO2003068161A2 Composition and method for protecting labile active components
08/21/2003WO2003068159A2 Compositions and methods for treating pain using cyclooxygenase-1 inhibitors
08/21/2003WO2003068156A2 Methods for treating or inhibiting sick building syndrome, post-lyme disease syndrome, and/or chronic fatigue syndrome
08/21/2003WO2003068153A2 CARDIAC-SPECIFIC 11β HYDROXYSTEROID DEHYDROGENASE TYPE 2 TRANSGENIC MICE
08/21/2003WO2003068148A2 Treatment of sleep disorders using sleep target modulators
08/21/2003WO2003068128A2 Massage appliance comprising a storage container and a setting mechanism for setting a characteristic massage value
08/21/2003WO2003060142A9 Compositions and methods for controlled release
08/21/2003WO2003055913A3 Secreted protein
08/21/2003WO2003054014A3 Apolipoprotein biopolymer markers predictive of alzheimers disease
08/21/2003WO2003048352A3 Histone h3 methyltransferase polypeptide
08/21/2003WO2003047579B1 Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
08/21/2003WO2003037254A3 Methods and compositions for the treatment and diagnosis of pain disorders using 46566
08/21/2003WO2003029451A3 Histone deacetylase 9
08/21/2003WO2003026632A3 Substituted phenol compounds useful for anesthesia and sedation
08/21/2003WO2003024404A3 Chemokines as adjuvants of immune response
08/21/2003WO2003004006A8 Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
08/21/2003WO2002100329A3 Methods and compositions for helping the body resist the effects of the aging process
08/21/2003WO2002098459A3 USE OF IgM ANTIBODIES AGAINST dsDNA IN SYSTEMIC LUPUS ERYTHEMATOSUS WITH NEPHRITIS
08/21/2003WO2002082075A3 Method for detecting chronic dementia diseases, and corresponding peptides and detection reagents
08/21/2003WO2002064748A3 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
08/21/2003WO2002058623A3 Inhibitors of spermidine synthase for the treatment of osteoarthritis and cartilage rehabilitation
08/21/2003WO2002056022A3 Diagnostics, drug screening and treatment for cancer
08/21/2003WO2002050545A3 Compositions and methods involving staphylococcus aureus protein staau-r9
08/21/2003WO2002050536A3 Replication assay for detecting anti-viral substances
08/21/2003WO2002044418A3 Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
08/21/2003WO2002044209A3 Cytonkine receptor zcytor19
08/21/2003WO2002036611A3 Immunomodulatory peptides derived from heat shock proteins and uses thereof
08/21/2003WO2002036162A3 Compositions for treatment of ocular neovascularization and neural injury
08/21/2003WO2002035240A3 Methods for identifying compounds for regulating muscle mass or function using vasoactive intestinal peptide receptors
08/21/2003WO2002020722A9 Methods and compositions for in vitro targeting
08/21/2003WO2001092581A3 Compositions and methods for the therapy and diagnosis of ovarian cancer
08/21/2003US20030159158 Method for identifying an agonist of neuronal calcium sensor-1 (NCS-1), for therapy of CNS disorders
08/21/2003US20030158398 Central nervous system disorders; psychological disorders
08/21/2003US20030158381 Novel insulin/igf/relaxin family polypeptides and dnas thereof
08/21/2003US20030158262 Ameliorating progression of amyotrophic lateral sclerosis
08/21/2003US20030158255 Use of bismuth subgallate in prevention and/or reduction of skin deterioration
08/21/2003US20030158248 N-(2-(1-amidinopyrrol-3-yl)ethyl)-5,6-dihydroxy-1-(2-(2-methox y-3-sulfatopropionylamino)-3-chloro-4-methylvaleroyl)indole-2-carboxamide
08/21/2003US20030158246 For the treatment of prostaglandin mediated diseases, such as allergic asthma or rhinitis.
08/21/2003US20030158244 Methods of treatment using a gastric retained losartan dosage
08/21/2003US20030158238 Treating diseases such as cancer, inflammatory disorders, restenosis,
08/21/2003US20030158237 Combination of antioxidant substances for the treatment of alzheimer's disease
08/21/2003US20030158223 Pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors
08/21/2003US20030158221 2-imidazomethyl- pyrido(4,3-b)indol-1-one or -carbazol-1-one derivatives containing an ester group; especially for treating irritable bowel syndrome.
08/21/2003US20030158217 Succinate and malonate complexes treatment of abnormal cell growth, such as cancer, and overexpression of erbB2, and inducing cell death
08/21/2003US20030158211 Methods and compositions for treatment of central nervous system disorders
08/21/2003US20030158187 Genetic polymorphisms in the preprotachy kinin gene
08/21/2003US20030158185 Novel use of phenylheteroakylamine derivatives
08/21/2003US20030158179 Quinoline derivatives
08/21/2003US20030158173 NK 1 antagonists
08/21/2003US20030158172 Treatment of behavioral disorders and cognitive activators by administering carboxypeptidase E enzyme inhibitors, penam and cephem beta -lactam antibiotics
08/21/2003US20030158168 Composition for combined use of aromatase inhibitors
08/21/2003US20030158162 Administering a therapeutically effective amount of an epoxy-steroidal aldosterone receptor antagonist that contains a 9,11-epoxy group to the patient for reducing intraocular pressure
08/21/2003US20030158159 Administering a calcitonin-like agent and a dehydroepiandrosterone-like agent to treat an indivisual for bone density loss
08/21/2003US20030158154 Vitamin D derivative is selected from calcitriol, alphacalcidol, 24,25-dihydroxy vitamin D3, and calcifediol, and bisphosphonate such as alendronic acid or salts or hydratess for bone disorders; improved combination
08/21/2003US20030158150 Combination therapy to treat hepatitis B virus
1 ... 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 ... 1151